Acetyldigitoxin
Acetyldigitoxin may decrease the cardiotoxic activities of Carboplatin.
Amikacin
Amikacin may increase the ototoxic activities of Carboplatin.
Ancestim
The risk or severity of cytotoxicity can be increased when Ancestim is combined with Carboplatin.
Advertisement
Anhydrous Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Carboplatin.
Anthrax immune globulin, human
The risk or severity of adverse effects can be increased when Carboplatin is combined with Anthrax immune globulin human.
Apalutamide
The serum concentration of Carboplatin can be decreased when it is combined with Apalutamide.
Advertisement
Arbekacin
Arbekacin may increase the ototoxic activities of Carboplatin.
BCG Vaccine
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Carboplatin.
BCG, Live, Connaught Strain
The risk or severity of adverse effects can be increased when Carboplatin is combined with Bacillus calmette-guerin substrain connaught live antigen.
Advertisement
BCG, Live, Tice Strain
The risk or severity of adverse effects can be increased when Carboplatin is combined with Bacillus calmette-guerin substrain tice live antigen.
Bevacizumab
Bevacizumab may increase the cardiotoxic activities of Carboplatin.
Bevacizumab-Awwb
Bevacizumab may increase the cardiotoxic activities of Carboplatin.
Bexarotene
The serum concentration of Bexarotene can be increased when it is combined with Carboplatin.
Cabazitaxel
Carboplatin may increase the myelosuppressive activities of Cabazitaxel.
Clozapine
The risk or severity of adverse effects can be increased when Carboplatin is combined with Clozapine.
Cyclophosphamide
Cyclophosphamide may increase the cardiotoxic activities of Carboplatin.
Cyclophosphamide Anhydrous
Cyclophosphamide may increase the cardiotoxic activities of Carboplatin.
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Carboplatin.
Deslanoside
Deslanoside may decrease the cardiotoxic activities of Carboplatin.
Digitoxin
Digitoxin may decrease the cardiotoxic activities of Carboplatin.
Digoxin
Digoxin may decrease the cardiotoxic activities of Carboplatin.
Dihydrostreptomycin
Dihydrostreptomycin may increase the ototoxic activities of Carboplatin.
Dipyrone
The risk or severity of myelosuppression can be increased when Metamizole is combined with Carboplatin.
Docetaxel
Carboplatin may increase the myelosuppressive activities of Docetaxel.
DOCETAXEL ANHYDROUS
Carboplatin may increase the myelosuppressive activities of Docetaxel.
Eltrombopag
The serum concentration of Carboplatin can be increased when it is combined with Eltrombopag.
Fingolimod
Carboplatin may increase the immunosuppressive activities of Fingolimod.
Fosphenytoin
The serum concentration of Fosphenytoin can be decreased when it is combined with Carboplatin.
Framycetin
Framycetin may increase the ototoxic activities of Carboplatin.
Gentamicin
Gentamicin may increase the ototoxic activities of Carboplatin.
Hepatitis A Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Carboplatin is combined with Hepatitis A Vaccine.
Hepatitis B Surface Antigen Vaccine
The risk or severity of adverse effects can be increased when Carboplatin is combined with Hepatitis B Vaccine (Recombinant).
Isavuconazole
The serum concentration of Carboplatin can be increased when it is combined with Isavuconazole.
Kanamycin
Kanamycin may increase the ototoxic activities of Carboplatin.
kanamycin A
Kanamycin may increase the ototoxic activities of Carboplatin.
Leflunomide
The risk or severity of adverse effects can be increased when Carboplatin is combined with Leflunomide.
Lipegfilgrastim
Carboplatin may increase the myelosuppressive activities of Lipegfilgrastim.
Natalizumab
The risk or severity of adverse effects can be increased when Carboplatin is combined with Natalizumab.
Neomycin
Neomycin may increase the ototoxic activities of Carboplatin.
Netilmicin
Netilmicin may increase the ototoxic activities of Carboplatin.
Ocrelizumab
Ocrelizumab may increase the immunosuppressive activities of Carboplatin.
Ouabain
Ouabain may decrease the cardiotoxic activities of Carboplatin.
Ovine Digoxin Immune Fab
Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Carboplatin.
Paclitaxel
Carboplatin may increase the myelosuppressive activities of Paclitaxel.
Paromomycin
Paromomycin may increase the ototoxic activities of Carboplatin.
Phenytoin
The serum concentration of Phenytoin can be decreased when it is combined with Carboplatin.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Carboplatin.
Plazomicin
Plazomicin may increase the ototoxic activities of Carboplatin.
Proscillaridin
Proscillaridin may decrease the cardiotoxic activities of Carboplatin.
Rabies Immune Globulin, Human
The risk or severity of adverse effects can be increased when Carboplatin is combined with Human rabies virus immune globulin.
Rabies Virus Vaccine Flury-Lep Strain
The risk or severity of adverse effects can be increased when Carboplatin is combined with Rabies virus inactivated antigen, A.
Roflumilast
Roflumilast may increase the immunosuppressive activities of Carboplatin.
Rolapitant
The serum concentration of Carboplatin can be increased when it is combined with Rolapitant.
ROTAVIRUS VACCINE, LIVE
The risk or severity of adverse effects can be increased when Carboplatin is combined with Rotavirus Vaccine.
Rubella Virus Vaccine Live (wistar Ra 27-3 Strain)
The risk or severity of adverse effects can be increased when Carboplatin is combined with Rubella virus vaccine.
Salmonella enterica subsp. enterica serovar typhi
The risk or severity of adverse effects can be increased when Carboplatin is combined with Salmonella typhi ty21a live antigen.
sipuleucel-T
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Carboplatin.
Sisomicin
Sisomicin may increase the ototoxic activities of Carboplatin.
Sorafenib
The risk or severity of adverse effects can be increased when Sorafenib is combined with Carboplatin.
Streptomycin
Streptomycin may increase the ototoxic activities of Carboplatin.
Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Carboplatin.
Teriflunomide
The serum concentration of Carboplatin can be increased when it is combined with Teriflunomide.
Tetanus Toxoid Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Carboplatin is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).
Tobramycin
Tobramycin may increase the ototoxic activities of Carboplatin.
Tofacitinib
Carboplatin may increase the immunosuppressive activities of Tofacitinib.
Topotecan
The risk or severity of adverse effects can be increased when Carboplatin is combined with Topotecan.
Trastuzumab
Trastuzumab may increase the cardiotoxic activities of Carboplatin.
Typhoid Vaccine Live Ty21a
The risk or severity of adverse effects can be increased when Carboplatin is combined with Salmonella typhi ty21a live antigen.
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain
The risk or severity of adverse effects can be increased when Carboplatin is combined with Salmonella typhi ty2 vi polysaccharide antigen.
Varicella Virus Vaccine Live (Oka-Merck) strain
The risk or severity of adverse effects can be increased when Carboplatin is combined with Varicella Zoster Vaccine (Live/Attenuated).
Vemurafenib
The serum concentration of Vemurafenib can be decreased when it is combined with Carboplatin.
Yellow Fever Vaccine
The risk or severity of adverse effects can be increased when Carboplatin is combined with Yellow Fever Vaccine.
Yellow-Fever Virus Vaccine, 17D-204 strain
The risk or severity of adverse effects can be increased when Carboplatin is combined with Yellow Fever Vaccine.
